Mitochondrial Peptides: A Research Reference

Mitochondria generate the ATP that powers nearly every cellular process, and their decline is one of the most consistently observed markers of biological aging and metabolic disease. Over the last two decades researchers have identified a class of endogenous and synthetic peptides — several encoded directly within mitochondrial DNA — that interact with mitochondrial membranes, bioenergetic pathways, and nuclear-mitochondrial signaling. This article summarizes what the published literature currently shows for four of the most-researched compounds in this space.

Reading the Evidence Tiers

• Clinical — human trial data exists (may be positive, mixed, or negative).
• Preclinical — animal or cell data only; no interventional human dosing trials published.

Preclinical findings do not guarantee equivalent effects in humans, and clinical findings are frequently mixed or trial-specific. This piece reports what was measured, not what a compound is presumed to do.

01 — SS-31 / Elamipretide (Clinical)

SS-31 is a four-amino-acid, cell-permeant peptide (D-Arg-Dmt-Lys-Phe-NH₂) with alternating cationic and aromatic residues. Identified during an opioid-receptor peptide screen, it shows no meaningful opioid activity; instead it concentrates 1,000–5,000-fold at the inner mitochondrial membrane, where it selectively associates with cardiolipin — the phospholipid required for organizing electron transport chain supercomplexes and preserving cristae structure. Also known as MTP-131 and Bendavia, it is the mitochondrial peptide that has moved furthest into human clinical development under sponsorship by Stealth BioTherapeutics.

Cited studies:

• Siegel et al., Aging Cell, 2013 — Short-term SS-31 in aged mice improved skeletal-muscle mitochondrial energetics and physical performance.
• Karaa et al., MMPOWER-3, Neurology, 2023 (NCT03323749) — Phase 3 trial in 218 adults with primary mitochondrial myopathy; 40 mg/day subcutaneous elamipretide for 24 weeks was well tolerated but did not separate from placebo on the 6-minute walk test — a key negative data point for this indication.
• Stealth OPUS-HF / PROGRESS-HF — Phase 2 trials in heart failure with reduced ejection fraction reported improvements in 6-minute walk distance and quality-of-life scores versus placebo.
• Reid Thompson et al., TAZPOWER, Genetics in Medicine — Tested elamipretide in Barth syndrome, a genetic disorder of defective cardiolipin remodeling.

Documented protocol as reported: Preclinical rodent studies used intraperitoneal daily injection. Clinical trials used subcutaneous self-administration at 40 mg/day for 24 weeks (with an open-label extension to 144 weeks in the MMPOWER program). Tolerability was good; the most common adverse events were mild-to-moderate injection-site reactions.

02 — MOTS-c (Preclinical)

MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA gene — one of the few known signaling peptides produced from mitochondrial rather than nuclear DNA. Under metabolic stress it translocates to the nucleus and regulates gene expression tied to antioxidant response and stress adaptation, acting largely through AMPK activation.

Cited studies:

• Lee, Zeng, Drew et al., Cell Metabolism, 2015 — Original discovery paper; MOTS-c promoted metabolic homeostasis and reduced obesity and insulin resistance in diet-induced obese mice.
• Reynolds et al., Cell Metabolism, 2018 — Described nuclear translocation of MOTS-c and AMPK-dependent regulation of nuclear gene expression under metabolic stress.
• Ming et al., BBRC, 2016 — MOTS-c reduced ovariectomy-induced bone loss in a rodent model via AMPK activation.
• Kong et al., Cell Reports, 2021 — Prevented pancreatic islet destruction in a mouse model of autoimmune diabetes.

As of this literature review, no peer-reviewed human trial has reported pharmacokinetic, pharmacodynamic, or outcome data for administered MOTS-c. Human evidence is limited to observational measurement of naturally circulating MOTS-c. Preclinical rodent parameters used intraperitoneal injection in diet-induced obese and aged mouse models over multi-week windows.

03 — NAD+ Precursors: NMN & NR (Clinical)

NAD+ is a dinucleotide cofactor — not a peptide — but is included here because it is consistently studied and stacked alongside mitochondrial peptides in the research literature. NAD+ acts as an obligate electron carrier for oxidative phosphorylation and a substrate for sirtuins, PARPs, and CD38. Cellular NAD+ falls with age; oral nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) reliably raise blood and tissue NAD+ in humans.

Cited studies:

• Martens et al. and pooled NR safety trials — NR at up to 2,000 mg/day for 12 weeks was safe and well tolerated, with reliable NAD+ increases.
• Brakedal et al., NADPARK Trial — 1,000 mg/day NR in newly diagnosed Parkinson's disease raised cerebrospinal-fluid NAD+ and altered mitochondrial-associated gene expression, with mild improvement in clinical symptom measures.
• Lapatto et al., Science Advances (twin study) — 20 BMI-discordant monozygotic twin pairs on escalating NR (250–1,000 mg/day) for 5 months improved NAD+ metabolism, muscle mitochondrial number, and myoblast differentiation, but did not improve adiposity or overall metabolic health.

Documented protocol as reported: Oral capsule/tablet in every cited human trial. NR dose range 250–2,000 mg/day, most commonly 300–1,000 mg/day. NMN preclinical dosing in mice: 100–300 mg/kg/day orally, for up to 12 months. Store at room temperature away from moisture and light per standard dietary-ingredient handling.

04 — Humanin (Preclinical)

Humanin was the first mitochondrial-derived peptide (MDP) identified, discovered in the early 2000s during a screen for factors that protect neurons from Alzheimer's-associated cell death. It is a 24-amino-acid peptide encoded within a mitochondrial rRNA region. Mechanistically it inhibits Bax-mediated apoptosis at the mitochondrion, binds IGFBP-3, and activates cell-survival signaling (ERK1/2, AKT, STAT3) through a cell-surface receptor complex.

Cited studies:

• Hashimoto et al., PNAS, 2001 — Original identification of humanin as a cytoprotective factor against neuronal Alzheimer-associated cell death.
• Ikonen et al., PNAS, 2003 — Humanin binds IGFBP-3, linking it to IGF-1 axis regulation of cell survival and apoptosis.
• Hoang et al., Metabolism, 2010 — Inhibited beta-cell apoptosis via STAT3 activation and delayed diabetes in NOD mice.
• IOVS retinal pigment epithelium study — Humanin protected RPE cells from oxidative stress, senescence, and mitochondrial dysfunction in AMD-relevant models.

As with MOTS-c, human interventional dosing data for administered humanin has not been published; the evidence base is preclinical and observational.

Reconstitution & Handling

The following reconstitution technique and calculations are reported consistently across the peptide research literature and apply to lyophilized research peptides generally.

• Concentration: mg/mL = vial mg ÷ diluent mL.
• Draw volume: mL to draw = target dose (mg) ÷ concentration (mg/mL).
• Diluent: Bacteriostatic water (0.9% benzyl alcohol) is standard for multi-use vials; preservative-free sterile water is used only for single-use preparations.
• Syringes: U-100 insulin syringes are the reported standard — 1 unit = 0.01 mL, so 100 units = 1 mL.
• Technique: Direct diluent slowly along the vial wall (never onto the powder) and swirl — never shake — until fully clear. Label every vial with compound, concentration, and reconstitution date.
• Storage: Lyophilized peptide frozen and light-protected; reconstituted solution refrigerated at 2–8 °C and used within the manufacturer- or study-specified window.

Research Status

None of the compounds discussed here — SS-31/Elamipretide, MOTS-c, NAD+ precursors, or Humanin — are FDA-approved for any indication as of this article's publication. BioPrime offers available reference compounds strictly for in-vitro and preclinical laboratory research conducted by qualified professionals.

References

• Siegel MP, et al. Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice. Aging Cell. 2013.
• Karaa A, et al. Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial. Neurology. 2023. NCT03323749.
• Alam N, et al. Contemporary insights into elamipretide's mitochondrial mechanism of action and therapeutic effects. Review, 2025.
• Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015;21:443–454. PMID 25738459.
• Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline. Cell Metabolism. 2018.
• Ming W, et al. Mitochondrial-derived peptide MOTS-c ameliorates ovariectomy-induced bone loss via AMPK activation. BBRC. 2016.
• Kong BS, et al. Mitochondrial-encoded MOTS-c prevents pancreatic islet destruction in autoimmune diabetes. Cell Reports. 2021.
• Martens CR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018.
• Brakedal B, et al. The NADPARK study: a randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease. Cell Metab. 2022.
• Lapatto HAK, et al. Nicotinamide riboside improves muscle mitochondrial biogenesis, satellite cell differentiation, and gut microbiota in a twin study. Science Advances. 2023.
• Hashimoto Y, et al. A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Aβ. PNAS. 2001.
• Ikonen M, et al. Interaction between the Alzheimer's survival peptide humanin and insulin-like growth factor-binding protein 3. PNAS. 2003.
• Hoang PT, et al. The neurosurvival factor humanin inhibits beta-cell apoptosis via STAT3 activation and delays and ameliorates diabetes in NOD mice. Metabolism. 2010.